Search Result

Targets Recommended:	BCRP

Results for "

breast

" in MCE Product Catalog:

By Targets:	BCRP (3) ADC Cytotoxin (1) Adenosine Receptor (1) Akt (8) AMPK (4) Androgen Receptor (1) Antibiotic (4) Antibody-Drug Conjugate (ADC) (2) Antifolate (1) Apoptosis (93) Aromatase (7) Aryl Hydrocarbon Receptor (3) ATM/ATR (1) ATP Synthase (1) Aurora Kinase (4) Autophagy (31) Bacterial (6) Bcl-2 Family (1) Bcr-Abl (4) c-Met/HGFR (1) Cathepsin (2) CDK (11) Checkpoint Kinase (Chk) (1) CXCR (4) Cytochrome P450 (1) Deubiquitinase (1) Discoidin Domain Receptor (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (3) Drug Metabolite (4) Drug-Linker Conjugates for ADC (1) E3 Ligase Ligand-Linker Conjugate (1) EGFR (7) Endogenous Metabolite (12) Endothelin Receptor (1) Epigenetic Reader Domain (5) ERK (1) Estrogen Receptor/ERR (35) Eukaryotic Initiation Factor (eIF) (1) FAK (2) Farnesyl Transferase (1) Ferroptosis (2) FGFR (2) FLT3 (1) Fungal (2) G-quadruplex (3) Glucosidase (1) Glutaminase (3) GnRH Receptor (2) GSK-3 (1) Hexokinase (1) Histone Acetyltransferase (2) Histone Methyltransferase (5) HIV (2) HSP (7) IGF-1R (2) Influenza Virus (2) Insulin Receptor (1) IRE1 (1) JAK (2) JNK (4) Lipoxygenase (1) LPL Receptor (1) MAGL (1) MDM-2/p53 (3) Melanocortin Receptor (1) MicroRNA (6) Microtubule/Tubulin (5) Mitochondrial Metabolism (2) Mitophagy (2) MMP (2) Monoamine Oxidase (1) Mps1 (1) NAMPT (1) NF-κB (2) Nucleoside Antimetabolite/Analog (1) p38 MAPK (1) Parasite (4) PARP (8) PD-1/PD-L1 (1) Phosphatase (2) PI3K (4) PI4K (1) Polo-like Kinase (PLK) (1) Potassium Channel (2) PPAR (2) PROTAC Linker (2) PROTACs (5) Protein Arginine Deiminase (1) Pyk2 (2) RAR/RXR (2) Ras (5) Reactive Oxygen Species (2) Ribosomal S6 Kinase (RSK) (1) ROCK (1) ROS (3) Sodium Channel (2) Src (3) STAT (5) Syk (2) Telomerase (1) TGF-beta/Smad (1) TGF-β Receptor (5) Toll-like Receptor (TLR) (1) Topoisomerase (6) ULK (4) VEGFR (3) Virus Protease (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (297) Cardiovascular Disease (8) Endocrinology (10) Infection (14) Inflammation/Immunology (26) Metabolic Disease (12) Neurological Disease (3)

By Targets:

BCRP (3)

ADC Cytotoxin (1)

Adenosine Receptor (1)

Akt (8)

AMPK (4)

Androgen Receptor (1)

Antibiotic (4)

Antibody-Drug Conjugate (ADC) (2)

Antifolate (1)

Apoptosis (93)

Aromatase (7)

Aryl Hydrocarbon Receptor (3)

ATM/ATR (1)

ATP Synthase (1)

Aurora Kinase (4)

Autophagy (31)

Bacterial (6)

Bcl-2 Family (1)

Bcr-Abl (4)

c-Met/HGFR (1)

Cathepsin (2)

CDK (11)

Checkpoint Kinase (Chk) (1)

CXCR (4)

Cytochrome P450 (1)

Deubiquitinase (1)

Discoidin Domain Receptor (1)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (3)

Drug Metabolite (4)

Drug-Linker Conjugates for ADC (1)

E3 Ligase Ligand-Linker Conjugate (1)

EGFR (7)

Endogenous Metabolite (12)

Endothelin Receptor (1)

Epigenetic Reader Domain (5)

ERK (1)

Estrogen Receptor/ERR (35)

Eukaryotic Initiation Factor (eIF) (1)

FAK (2)

Farnesyl Transferase (1)

Ferroptosis (2)

FGFR (2)

FLT3 (1)

Fungal (2)

G-quadruplex (3)

Glucosidase (1)

Glutaminase (3)

GnRH Receptor (2)

GSK-3 (1)

Hexokinase (1)

Histone Acetyltransferase (2)

Histone Methyltransferase (5)

HIV (2)

HSP (7)

IGF-1R (2)

Influenza Virus (2)

Insulin Receptor (1)

IRE1 (1)

JAK (2)

JNK (4)

Lipoxygenase (1)

LPL Receptor (1)

MAGL (1)

MDM-2/p53 (3)

Melanocortin Receptor (1)

MicroRNA (6)

Microtubule/Tubulin (5)

Mitochondrial Metabolism (2)

Mitophagy (2)

MMP (2)

Monoamine Oxidase (1)

Mps1 (1)

NAMPT (1)

NF-κB (2)

Nucleoside Antimetabolite/Analog (1)

p38 MAPK (1)

Parasite (4)

PARP (8)

PD-1/PD-L1 (1)

Phosphatase (2)

PI3K (4)

PI4K (1)

Polo-like Kinase (PLK) (1)

Potassium Channel (2)

PPAR (2)

PROTAC Linker (2)

PROTACs (5)

Protein Arginine Deiminase (1)

Pyk2 (2)

RAR/RXR (2)

Ras (5)

Reactive Oxygen Species (2)

Ribosomal S6 Kinase (RSK) (1)

ROCK (1)

ROS (3)

Sodium Channel (2)

Src (3)

STAT (5)

Syk (2)

Telomerase (1)

TGF-beta/Smad (1)

TGF-β Receptor (5)

Toll-like Receptor (TLR) (1)

Topoisomerase (6)

ULK (4)

VEGFR (3)

Virus Protease (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (297)

Cardiovascular Disease (8)

Endocrinology (10)

Infection (14)

Inflammation/Immunology (26)

Metabolic Disease (12)

Neurological Disease (3)

301

Inhibitors & Agonists

Screening Libraries

Dye Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas

HY-122878

HS-131	HSP	Cancer
HS-131, a near infrared dye tethered Hsp90 inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers.

HY-115514A

BRK inhibitor P21d hydrochloride	Others	Cancer
BRK inhibitor P21d hydrochloride is a potent breast tumor kinase (BRK/PTK6) inhibitor with an IC₅₀ of 30 nM. BRK inhibitor P21d hydrochloride inhibits p-SAM68 with an IC₅₀ of 52 nM. BRK inhibitor P21d hydrochloride can be used to evaluate the in vivo activity of BRK inhibitors in xenograft breast tumor models.

HY-108638

NSC 146109 hydrochloride	MDM-2/p53 Apoptosis	Cancer
NSC 146109 hydrochloride is a small-molecule p53 activator that target MDMX and can be used for breast cancer research. NSC 146109 hydrochloride is a pseudourea derivative, promotes breast cancer cells to undergo apoptosis through activating p53 and inducing expression of proapoptotic genes.

HY-101120

666-15
Epigenetic Reader Domain Cancer

666-15 is a potent and selective CREB inhibitor with an IC₅₀ of 81 nM. 666-15 suppresses tumor growth in a breast cancer xenograft model.

666-15	Epigenetic Reader Domain	Cancer
666-15 is a potent and selective CREB inhibitor with an IC₅₀ of 81 nM. 666-15 suppresses tumor growth in a breast cancer xenograft model.

HY-13738

Raloxifene Keoxifene; LY156758 free base; LY139481	Estrogen Receptor/ERR	Cancer
Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research.

HY-13442

Eribulin B1939; E7389; ER-086526	Microtubule/Tubulin Apoptosis	Cancer
Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

HY-13442A

Eribulin mesylate B1939 mesylate; E7389 mesylate; ER-086526 mesylate	Microtubule/Tubulin Apoptosis	Cancer
Eribulin mesylate (E7389 mesylate) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

HY-138642

ARV-471
Estrogen Receptor/ERR PROTACs Cancer

ARV-471 is a best-in-class, orally active estrogen receptor (ER) PROTAC degrader. ARV-471 is developed for the research of breast cancer.

ARV-471	Estrogen Receptor/ERR PROTACs	Cancer
ARV-471 is a best-in-class, orally active estrogen receptor (ER) PROTAC degrader. ARV-471 is developed for the research of breast cancer.

HY-N2547

Steviolbioside	Others	Cancer
Steviolbioside is a rare sweetener that exists in stevia rebaudiana leaves. Steviolbioside presents inhibition on several human cancer cells and acts as potential remedy for human breast cancer.

HY-N1823

Pygenic acid A	Apoptosis	Cancer Metabolic Disease Inflammation/Immunology
Pygenic acid A is a natural compound that can be found in Prunella vulgaris. Pygenic acid A induces apoptosis in metastatic breast cancer cells. Pygenic acid A can be used for the research of diabetes, inflammatory diseases, and cancers.

HY-W010248

2-Phenylglycine
DL-α-Phenylglycine
Endogenous Metabolite Metabolic Disease

2-Phenylglycine (DL-α-Phenylglycine) is a metabolite in breast milk during the W2 to W4 lactation period.

2-Phenylglycine DL-α-Phenylglycine	Endogenous Metabolite	Metabolic Disease
2-Phenylglycine (DL-α-Phenylglycine) is a metabolite in breast milk during the W2 to W4 lactation period.

HY-14248

Letrozole CGS 20267	Aromatase Autophagy	Cancer
Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC₅₀ of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer.

HY-N3442

Juglanin	JNK Apoptosis Autophagy	Cancer Inflammation/Immunology
Juglanin, a natural occurring flavonoid, is a JNK acticator, with inflammation and anti-tumor activities. Juglanin can induce apoptosis and autophagy on human breast cancer cells.

HY-133118

6RK73	Deubiquitinase	Cancer
6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC₅₀ of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC₅₀=236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer.

HY-132294

GNE-502
Estrogen Receptor/ERR Cancer

GNE-502 is an orally active and potent degrader for estrogen receptor (ER). GNE-502 can be used for the research of breast cancer.

GNE-502	Estrogen Receptor/ERR	Cancer
GNE-502 is an orally active and potent degrader for estrogen receptor (ER). GNE-502 can be used for the research of breast cancer.

HY-119808

Terrein	Melanocortin Receptor Apoptosis Antibiotic	Cancer
Terrein is a melanogenesis inhibitor. Terrein induces apoptosis in breast cancer cell lines . Terrein is an inhibitor of quorum sensing and c-di-GMP in Pseudomonas aeruginosa.

HY-136447

ASP4132	AMPK	Cancer
ASP4132 is an orally active, potent AMPK activator with an EC₅₀ of 18 nM. ASP4132 has anti-cancer activity and makes tumor regression in breast cancer xenograft mouse models.

HY-110182

SP-141	MDM-2/p53	Cancer
SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells.

HY-112162

BOS-172722	Mps1	Cancer
BOS-172722 is an inhibitor of monopolar spindle 1 (MPS1) checkpoint with an IC₅₀ of 11 nM and 63 nM for MPS1 (1 mM ATP) and P-MPS1, respectively. BOS-172722 also has potential for the study of various forms of breast cancer.

HY-116896

LY117018
Estrogen Receptor/ERR Cancer

LY117018, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 exerts antiproliferative effects on breast cancer cell lines.

LY117018	Estrogen Receptor/ERR	Cancer
LY117018, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 exerts antiproliferative effects on breast cancer cell lines.

HY-101447A

SI-2 hydrochloride EPH 116 hydrochloride	Others	Cancer
SI-2 (EPH 116 hydrochloride) is a highly promising SRC-3 inhibitor (PPI), with IC₅₀ values of 3-20 nM for breast cancer cell death. SI-2 (EPH 116 hydrochloride) has a much improved toxicity and pharmacokinetic profile, with acceptable oral availability.

HY-139376

FGFR1 inhibitor-2	FGFR	Cancer
FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC₅₀ is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer.

HY-B0448A

Phenytoin sodium 5,5-Diphenylhydantoin sodium salt	Sodium Channel Virus Protease	Neurological Disease
Phenytoin sodium (5,5-Diphenylhydantoin sodium salt) is a potent Voltage-gated Na⁺ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice.

HY-B0448

Phenytoin 5,5-Diphenylhydantoin	Sodium Channel Virus Protease	Neurological Disease
Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na⁺ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice.

HY-W011338

Benzyl butyl phthalate	Aryl Hydrocarbon Receptor	Cancer
Benzyl butyl phthalate, a member of phthalic acid esters (PAEs), can trigger the migration and invasion of hemangioma (HA) cells via upregulation of Zeb1. Benzyl butyl phthalate activates aryl hydrocarbon receptor (AhR) in breast cancer cells to stimulate SPHK1/S1P/S1PR3 signaling and enhances formation of metastasis-initiating breast cancer stem cells (BCSCs).

HY-B0628B

Vinflunine ditartrate	Microtubule/Tubulin	Cancer
Vinflunine ditartrate is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family. Vinflunine ditartrate has anti-angiogenic, vascular-disrupting and anti-metastatic activities. Vinflunine ditartrate can be used for the research of transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and carcinoma of the breast.

HY-136255

Camizestrant AZD-9833	Estrogen Receptor/ERR	Cancer
Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER⁺ HER2-advanced breast cancer.

HY-N6007

Chrysosplenol D	Apoptosis	Cancer Infection Inflammation/Immunology
Chrysosplenol D is a methoxy flavonoid that induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Chrysosplenol D also exhibits anti-inflammatory and moderate antitrypanosomal activities.

HY-N2059

Santalol	Others	Cancer
Santalol is a mixture of α and β-isomer santalol. α-santalol is isolated from sandalwood oil. α-santalol is a promising anti-cancer agent against cancers such as oral, breast, prostate and skin cancer.

HY-135276

Targaprimir-96	MicroRNA Apoptosis	Cancer
Targaprimir-96 is a potent inhibitor of microRNA-96 (miR-96) processing. Targaprimir-96 selectively modulates miR-96 production in cancer cells and triggers apoptosis. Targaprimir-96 binds primary miR-96 (pri-miR-96) with low nanomolar affinity. Targaprimir-96 directly engages pri-miR-96 in breast cancer cells and is ineffective on healthy breast cells.

HY-W005288

4-Vinylphenol	Apoptosis Endogenous Metabolite	Cancer
4-Vinylphenol is found in the medicinal herb Hedyotis diffusa Willd, wild rice and is also the metabolite of p-coumaric and ferulic acid by lactic acid bacteria in wine. 4-Vinylphenol induces apoptosis and inhibits blood vessels formation and suppresses invasive breast tumor growth in vivo.

HY-N0595

Genistin Genistine; Genistoside; Genistein 7-O-β-D-glucopyranoside	Estrogen Receptor/ERR Apoptosis	Cancer Metabolic Disease
Genistin (Genistine), an isoflavone belonging to the phytoestrogen family, is a potent anti-adipogenic and anti-lipogenic agent. Genistin attenuates cellular growth and promotes apoptotic cell death breast cancer cells through modulation of ERalpha signaling pathway.

HY-120140

Ganoderic acid DM	Apoptosis PI3K	Cancer Metabolic Disease Inflammation/Immunology
Ganoderic acid DM, a natural triterpenoid isolated from Ganoderma lucidum, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Ganoderic acid DM as a specific inhibitor of osteoclastogenesis.

HY-135276A

Targaprimir-96 TFA	MicroRNA Apoptosis	Cancer
Targaprimir-96 TFA is a potent inhibitor of microRNA-96 (miR-96) processing. Targaprimir-96 TFA selectively modulates miR-96 production in cancer cells and triggers apoptosis. Targaprimir-96 TFA binds primary miR-96 (pri-miR-96) with low nanomolar affinity. Targaprimir-96 TFA directly engages pri-miR-96 in breast cancer cells and is ineffective on healthy breast cells.

HY-101923B

LYN-1604 dihydrochloride	ULK Autophagy Apoptosis	Cancer
LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC).

HY-101923A

LYN-1604 hydrochloride	ULK Autophagy Apoptosis	Cancer
LYN-1604 hydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC).

HY-101923

LYN-1604
ULK Autophagy Apoptosis Cancer

LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC).

LYN-1604	ULK Autophagy Apoptosis	Cancer
LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC).

HY-137552

MKI-1 MASTL Kinase Inhibitor-1	Others	Cancer
MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC₅₀ of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer.

HY-18766

EW-7195	TGF-β Receptor p38 MAPK	Cancer
EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC₅₀ of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung.

HY-12352A

HJC0416 hydrochloride	STAT Apoptosis	Cancer
HJC0416 hydrochloride is a potent and orally active STAT3 inhibitor with an enhanced anticancer profile than Stattic (HY-13818). HJC0416 hydrochloride is a promising anti-cancer agent for breast cancer study.

HY-117102

ANI-7	Aryl Hydrocarbon Receptor Checkpoint Kinase (Chk)	Cancer
ANI-7 is an activator of aryl hydrocarbon receptor (AhR) pathway. ANI-7 inhibits the growth of multiple cancer cells, and potently and selectively inhibits the growth of MCF-7 breast cancer cells with a GI₅₀ of 0.56 μM. ANI-7 induces CYP1-metabolizing mono-oxygenases by activating AhR pathway, and also induces DNA damage, checkpoint Kinase 2 (Chk2) activation, S-phase cell cycle arrest, and cell death in sensitive breast cancer cell lines.

HY-N3995

5β-Dihydrocortisol	Apoptosis Drug Metabolite	Cancer
5β-Dihydrocortisol, a metabolite of Cortisol, is a potential mineralocorticoid. 5β-Dihydrocortisol can potentiate glucocorticoid activity in raising the intraocular pressure. 5β-Dihydrocortisol causes breast cancer cell apoptosis.

HY-123604A

TH1834 dihydrochloride	Histone Acetyltransferase Apoptosis	Cancer
TH1834 dihydrochloride is a specific Tip60 (KAT5) histone acetyltransferase inhibitor. TH1834 dihydrochloride induces apoptosis and increases DNA damage in breast cancer. TH1834 dihydrochloride does not affect the activity of related histone acetyltransferase MOF. Anticancer activity.

HY-123604

TH1834	Histone Acetyltransferase Apoptosis	Cancer
TH1834 is a specific Tip60 (KAT5) histone acetyltransferase (HAT) inhibitor. TH1834 induces apoptosis and increases DNA damage in breast cancer. TH1834 does not affect the activity of related histone acetyltransferase MOF. Anticancer activity.

HY-139180

PRGL493	Others	Cancer
PRGL493 is a potent and selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor. PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research.

HY-100608

BMS453 BMS-189453	RAR/RXR	Cancer
BMS453 (BMS-189453), a synthetic retinoid, is a RARβ agonist and a RARα/RARγ antagonist. BMS453 inhibits breast cell growth predominantly through the induction of active TGFβ.

HY-111538

MAGL-IN-1	MAGL	Cancer
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC₅₀ of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays.

HY-N8122

24-Methylenecycloartanyl ferulate	Akt	Cancer
24-Methylenecycloartanyl ferulate is a γ-oryzanol compound. 24-Methylenecycloartanyl ferulate promotes parvin-beta expression in human breast cancer cells. 24-Methylenecycloartanyl ferulate is a potential ATP-competitive Akt1 inhibitor (EC₅₀= 33.3μM).

HY-18959

CWP232228	β-catenin Wnt	Cancer
CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs).

HY-107096

CH-0793076 TP3076	Topoisomerase	Cancer
CH-0793076 (TP3076), a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 inhibits DNA topoisomerase I with an IC₅₀ of 2.3 μM. CH-0793076 is efficacious against cells expressing BCRP (breast cancer resistance protein).

HY-N7695

Physalin B	Apoptosis Autophagy	Cancer
Physalin B, one of the major active steroidal constituents of Cape gooseberry, induces cell cycle arrest and triggers apoptosis in breast cancer cells through modulating p53-dependent apoptotic pathway. Physalin B inhibits the ubiquitin-proteasome pathway and induces incomplete autophagic response in human colon cancer cells in vitro.

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Cancer Endocrinology
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.

HY-132194

ERα degrader-2	Estrogen Receptor/ERR	Cancer
ERα degrader-2 is a selective estrogen receptor degrader (SERD) with potent binding affinity with ERα (IC₅₀=17.1 nM), good degradation efficacy (EC₅₀=0.3 nM). ERα degrader-2 exhibits favorable pharmacokinetic properties and excellent druggability, can be used for HER⁺ breast cancer research.

HY-13673A

Goserelin acetate ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.

HY-107096B

CH-0793076 TFA TP3076 TFA	Topoisomerase	Cancer
CH-0793076 (TP3076) TFA, a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 TFA inhibits DNA topoisomerase I with an IC₅₀ of 2.3 μM. CH-0793076 TFA is efficacious against cells expressing BCRP (breast cancer resistance protein).

HY-136453

CR-1-31-B	Eukaryotic Initiation Factor (eIF)	Cancer
CR-1-31-B is a potent eIF4A RNA helicase inhibitor. CR-1-31-B blocks MUC1-C translation in response to growth factor stimulation in breast cancer cells.

HY-103457

Y134	Estrogen Receptor/ERR	Cancer
Y134 is a selective and orally active oestrogen receptor (ER) modulator (SERM), exhibits potent antagonist activity at ERα and ERβ. Y134 shows 121.1-fold selectivity for ERα (K_i=0.09 nM) over ERβ (K_i=11.31 nM). Y134 inhibits oestrogen-stimulated proliferation of ER-positive human breast cancer cells.

HY-N2098

Obtusifolin	NF-κB	Cancer
Obtusifolin, isolated from the seeds of Cassia obtusifolia, regulates the gene expression and production of MUC5AC mucin in airway epithelial cells via inhibiting NF-kB pathway. Obtusifolin suppresses phthalate esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein.

HY-18619

YL-109	Aryl Hydrocarbon Receptor	Cancer
YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness.

HY-119437

FLTX1	Estrogen Receptor/ERR	Cancer
FLTX1 is a fluorescent Tamoxifen derivative that can specifically label intracellular Tamoxifen-binding sites (estrogen receptors) under permeabilized and non-permeabilized conditions. FLTX1 exhibits the potent antiestrogenic properties of Tamoxifen in breast cancer cells. FLTX1 is devoid of the estrogenic agonistic effect on the uterus.

HY-13686

PQ401	IGF-1R Apoptosis	Cancer
PQ401 is a potent inhibitor of IGF-IR signaling. PQ401 inhibits IGF-I-stimulated IGF-IR autophosphorylation with an IC₅₀ of 12.0 μM in a series of studies in MCF-7 cells. PQ401 is effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC₅₀, 6 μM). PQ401 is a potential agent for breast and other IGF-I-sensitive cancers. PQ401 induces caspase-mediated apoptosis.

HY-131339

SP-96	Aurora Kinase	Cancer
SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC₅₀=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI₅₀=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC).

HY-130851

HS-27	HSP	Cancer
HS-27, a fluorescently-tethered Hsp90 inhibitor, assays surface Hsp90 expression on intact tissue specimens. HS-27 is made up of the core elements of SNX-5422, an Hsp90 inhibitor, tethered via a PEG linker to a fluorescein derivative (fluorescein isothiocyanate or FITC), that binds to ectopically expressed Hsp90. HS-27 has potential use in a see-and-treat paradigm in breast cancer.

HY-132305

VEGFR-3-IN-1	VEGFR	Cancer
VEGFR-3-IN-1 is a potent and selective VEGFR3 inhibitor with an IC₅₀ of 110.4 nM. VEGFR-3-IN-1 significantly inhibits proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway, and also effectively inhibits breast cancer growth.

HY-N6885

Puerarin-4'-O-β-D-glucopyranoside	Others	Cancer
Puerarin-4'-O-β-D-glucopyranoside (compound 8) is a isoflavone from Pueraria lobata root (PLR). Puerarin-4'-O-β-D-glucopyranoside has estrogenic activity and anti-proliferation of MCF-7 human breast carcinoma cells.

HY-133017

Amcenestrant SAR439859	Estrogen Receptor/ERR	Cancer
SAR439859 (compound 43d) is an orally active, nonsteroidal and selective estrogen receptor degrader (SERD). SAR439859 is a potent ER antagonist and has ER degrading activity with an EC₅₀ of 0.2 nM for ERα degradation. SAR439859 demonstrates robust antitumor efficacy and limited cross-resistance in ER⁺ breast cancer.

HY-133129

MS1943	Histone Methyltransferase Apoptosis	Cancer
MS1943 is a first-in-class, orally bioavailable EZH2 selective degrader, with an IC₅₀ of 120 nM. MS1943 significantly reduces EZH2 protein levels in numerous triple-negative breast cancer (TNBC) and other cancer and noncancerous cell lines. MS1943 effectively blocks proliferation of multiple TNBC and other cancer cell lines.

HY-108232

MK-2206	Akt Autophagy Apoptosis	Cancer
MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC₅₀s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. Anticancer activities.

HY-126222

MitoTam bromide, hydrobromide	Apoptosis Mitochondrial Metabolism	Cancer
MitoTam bromide, hydrobromide, a Tamoxifen derivative, is an electron transport chain (ETC) inhibitor. MitoTam bromide, hydrobromide reduces mitochondrial membrane potential in senescent cells and affects mitochondrial morphology. MitoTam bromide, hydrobromide is an effective anticancer agent, suppresses respiratory complexes (CI-respiration) and disrupts respiratory supercomplexes (SCs) formation in breast cancer cells.

HY-14833

Atiratecan TP300	Others	Cancer
Atiratecan (TP300) is a prodrug of camptothecin analog CH0793076 (HY-107096). Atiratecan does not inhibit acetylcholinesterase (AChE) activities. Atiratecan shows antitumor activity against both breast cancer resistance protein (BCRP)-positive and -negative xenografts in mouse xenograft models.

HY-126222A

MitoTam iodide, hydriodide	Apoptosis Mitochondrial Metabolism	Cancer
MitoTam iodide, hydriodide is a Tamoxifen derivative, an electron transport chain (ETC) inhibitor, spreduces mitochondrial membrane potential in senescent cells and affects mitochondrial morphology. MitoTam iodide, hydriodide is an effective anticancer agent, suppresses respiratory complexes (CI-respiration) and disrupts respiratory supercomplexes (SCs) formation in breast cancer cells. MitoTam iodide, hydriodide causes apoptosis.

HY-N2666

5α-Hydroxycostic acid	VEGFR	Cancer
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating VEGF/VEGFR2 and Ang2/Tie2 pathways.

HY-136244

PF-06952229	TGF-β Receptor	Cancer
PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer.

HY-N0292

Oleuropein	PPAR Apoptosis Aromatase	Cancer Inflammation/Immunology Cardiovascular Disease
Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity. Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase.

HY-B2099

Buformin 1-Butylbiguanide	AMPK	Cancer Metabolic Disease
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).

HY-B2099A

Buformin hydrochloride 1-Butylbiguanide hydrochloride	AMPK	Cancer
Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).

HY-125209A

TH5427 hydrochloride	DNA/RNA Synthesis	Cancer
TH5427 hydrochloride is a potent, selective NUDT5 inhibitor (IC₅₀=29 nM). TH5427 hydrochloride shows an apparent 690-fold selectivity for NUDT5 over MTH1. TH5427 hydrochloride blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells.

HY-124822

COH-SR4	AMPK	Cancer Metabolic Disease
COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders.

HY-P9907

Trastuzumab Anti-Human HER2, Humanized Antibody	EGFR	Cancer
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-138295

KRAS inhibitor-10	Ras	Cancer
KRAS inhibitor-10 selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1.

HY-126005

VGSC blocker-1		Cancer
VGSC blocker-1 is a potent and small molecule blocker of neonatal isoform of the VGSC subtype, Nav1.5 (nNav1.5). VGSC blocker-1 blocks INa peak currents 34.9% at 1 μM and inhibits cell invasion 0.3% at 1 μM in human breast cancer cell line MDA-MB-231, without affecting the cell viability.

HY-N3032

Xanthatin	Apoptosis VEGFR Lipoxygenase Bacterial	Cancer Infection Inflammation/Immunology
Xanthatin is isolated from Xanthium strumarium leaves. Xanthatin exhibits strong antitumor activities against a variety of cancer cells through apoptosis persuasion and shows anti-inflammatory activities by inhibiting PGE2 synthesis and 5-lipoxygenase activity. Xanthatin is a potent and orally active inhibitor of VEGFR2 kinase activity with an IC₅₀ of 3.8 μM and prominently blocks the phosphorylation of VEGFR2 at Tyr951 site. Xanthatin inhibits angiogenesis and has the potential for the investigation of breast cancer.

HY-15731

Estetrol	Estrogen Receptor/ERR Endogenous Metabolite	Cardiovascular Disease
Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast.

HY-138657

NCGC00378430	Phosphatase	Cancer
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor. NCGC00378430 partially reverses transcriptional and metabolic profiles mediated by SIX1 overexpression and reverses SIX1-induced TGF-β signaling and epithelial-mesenchymal transition (EMT). NCGC00378430 inhibits SIX1-mediated breast cancer metastasis in a mouse model.

HY-U00073

Benin
Butocin; Butocine
Others Cancer

Benin is a potent cytostatic drug that can be used for the treatment of generalized carcinoma of the breast.

HY-119906

Conglobatin FW-04-806	HSP Apoptosis	Cancer
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo.

HY-W004307

Octadecanal
Endogenous Metabolite Others

Octadecanal is a long-chain aldehyde, present in both thigh and breast muscle.

HY-14590

Kaempferol Kempferol; Robigenin	Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite	Cancer
Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer.

HY-14586

Irosustat
STX64; BN83495; 667-Coumate
Others Cancer

Irosustat is a potent steroid sulfatase inhibitor, with an IC₅₀ of 8 nM, and exhibits anti-breast cancer activity.

HY-13757

Tamoxifen Citrate ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate	Estrogen Receptor/ERR HSP Autophagy Apoptosis	Cancer
Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 µM and 1.8 µM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis.

HY-13724B

Pipendoxifene hydrochloride	Estrogen Receptor/ERR	Cancer
Pipendoxifene hydrochloride is a selective estrogen receptor modulator (SERM) that can be used for the research of breast cancer.

HY-B1012

Quinestrol W-3566	Estrogen Receptor/ERR	Endocrinology Cancer
Quinestrol is a synthetic estrogen, used in hormone replacement therapy, and occasionally to treat breast cancer and prostate cancer

HY-B0412

Estriol Oestriol	Estrogen Receptor/ERR Endogenous Metabolite	Cancer
Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells.

HY-19971

ML239
Others Cancer

ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC₅₀ of 1.16 μM.
HY-N6820

Iristectorin A
Others Cancer

Iristectorin A, a natural product from Iris tectorum, has anti-cancer activities in breast cancer.
HY-N6819

Iristectorin B
Others Cancer

Iristectorin B is an isoflavone from Iris tectorum, has anti-cancer activities in breast cancer.
HY-12015

Iniparib
BSI-201; NSC-746045; IND-71677
PARP Influenza Virus Cancer

Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

HY-123938

CYH33	PI3K	Cancer
CYH33 is an orally active, highly selective PI3Kα inhibitor with IC₅₀s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively. CYH33 inhibits phosphorylation of Akt, ERK and induces significant G1 phase arrest in breast cancer cells and non-small cell lung cancer (NSCLC) cells. CYH33 has potent activity against solid tumors.

HY-13757A

Tamoxifen ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen	Estrogen Receptor/ERR HSP Autophagy Apoptosis	Cancer
Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 µM and 1.8 µM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse.

HY-128962

AZ1508
MC-Lys-MMETA
Drug-Linker Conjugates for ADC Cancer

AZ1508 is a drug-linker conjugates for ADC for the treatment of breast and stomach cancer, and the drug is a tubulin inhibitor.
HY-P9912

Pertuzumab
EGFR Cancer

Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
HY-100390

(S)-ML753286
BCRP Cancer

(S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor with an IC₅₀ of 0.6 μM on BCRP efflux transporter.

HY-108315

6-Aminochrysene 6-Chrysenamine	Others	Cancer Inflammation/Immunology
6-Aminochrysene (6-Aminochrysene) is an aromatic amine used as a chemotherapeutic agent in the treatment of splenomegaly, myeloid leukemia, and breast cancer.

HY-135699

TD52	Apoptosis Phosphatase Akt	Cancer
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity.

HY-P9912A

Pertuzumab (PBS)
EGFR Cancer

Pertuzumab (PBS), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-128553

Antineoplaston A10	Ras Apoptosis Endogenous Metabolite	Cancer
Antineoplaston A10, a naturally occurring substance in human body, is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.

HY-125848

Ginsenoside F2	Apoptosis Autophagy Endogenous Metabolite	Cancer
Ginsenoside F2, a metabolite from Ginsenoside Rb1, induces apoptosis accompanied by protective autophagy in breast cancer stem cells.

HY-107309

Scabioside C
Others Cancer

Scabioside C is a main triterpenoid saponin for total secondary saponin (TSS). TSS, from A. raddeana, exhibits the potential anti-breast cancer effect.

HY-125465

SLLN-15	Autophagy	Cancer
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).

HY-124632

WJ460
Others Cancer

WJ460 is a potent myoferlin (MYOF) inhibitor, which interacts directly with MYOF and exerts anti-metastatic activity in the nanomolar range in breast cancer cells.
HY-N8187

Eupalinolide O
Apoptosis Cancer

Eupalinolide O is a sesquiterpene lactone with anticancer activities. Eupalinolide O induces cell apoptosis in human MDA-MB-468 breast cancer cells.

HY-128553A

(Rac)-Antineoplaston A10	Ras Apoptosis	Cancer
(rac)-Antineoplaston A10 is the racemate of Antineoplaston A10. Antineoplaston A10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.

HY-N3755

Dihydroresveratrol	Estrogen Receptor/ERR	Cancer
Dihydroresveratrol, a potent phytoestrogen, is a hormone receptor modulator. Dihydroresveratrol exhibits proliferative effects in androgen-independent prostate and breast cancer cells at picomolar and nanomolar concentrations.

HY-18719A

Endoxifen Z-isomer hydrochloride	Estrogen Receptor/ERR Potassium Channel	Cancer
Endoxifen Z-isomer hydrochloride is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα).

HY-N4010

Iriflophenone
Others Cancer

Iriflophenone, isolated from Aquilaria sinensis, stimulates MCF-7 and T-47D human breast cancer cells proliferation.

HY-111645

3-Methylcytidine	Nucleoside Antimetabolite/Analog	Cancer
3-Methylcytidine, a urinary nucleoside, can be used as a biomarker of four different types of cancer: lung cancer, gastric cancer, colon cancer, and breast cancer.

HY-18719

Endoxifen (Z-isomer)	Estrogen Receptor/ERR Potassium Channel	Cancer
Endoxifen Z-isomer is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα).

HY-17557

Calcium N5-methyltetrahydrofolate NSC173328	Antifolate	Cancer
Calcium N5-methyltetrahydrofolate(NSC173328) is the calcium salt of levomefolic acid, which has been proposed for treatment of cardiovascular disease and advanced cancers such as breast and colorectal cancers.

HY-B0323

Sulfisoxazole Sulfafurazole	Bacterial Endothelin Receptor Antibiotic	Cancer Infection Endocrinology
Sulfisoxazole (Sulfafurazole), an endothelin receptor antagonist, is a sulfonamide antibacterial with an oxazole substituent. Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A.

HY-136552

β-Bisabolene	Others	Cancer
β-Bisabolene is a sesquiterpene isolated from opoponax (Commiphora guidotti). β-Bisabolene, an anti-cancer agent, can be used for the study of breast cancer.

HY-N0399

Wogonoside	Autophagy	Cancer Inflammation/Immunology
Wogonoside, a flavonoid glycoside isolated from Huangqin, possesses anti-inflammatory effects. Wogonoside induces autophagy in breast cancer cells by regulating MAPK-mTOR pathway.

HY-18719B

Endoxifen hydrochloride	Estrogen Receptor/ERR Drug Metabolite Parasite Aromatase	Cancer
Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study.

HY-100395

F16	Apoptosis	Cancer
F16 is a potent growth inhibitor of the *neu-overexpressing cells and also selectively inhibits proliferation of mammary epithelial as well as a variety of mouse mammary tumor and human breast* cancer cell lines.

HY-18719E

Endoxifen	Estrogen Receptor/ERR Aromatase Drug Metabolite Parasite	Cancer
Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study.

HY-110244

Tilfrinib	Others	Cancer
Tilfrinib (compound 4f) is a potent and selective inhibitor of breast tumor kinase (Brk) with an IC₅₀ of 3.15 nM, which displays anti-proliferative activity and acts as a promising antitumor agent.

HY-N2483

Hydroprotopine	Others	Cancer
Hydroprotopine is a alkaloid from Hypecoum leptocarpumand. Leptopidine can suppress growth and induce cytotoxicity in breast cancer cells and that the cytotoxicity of leptopidine may be related to its inhibitory effect on fatty acid synthase expression.

HY-123918

JMS-17-2	Others	Cancer Endocrinology
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC₅₀ of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells.

HY-123918A

JMS-17-2 hydrochloride	Others	Cancer Endocrinology
JMS-17-2 hydrochloride is a potent and selective CX3CR1 antagonist with an IC₅₀ of 0.32 nM. JMS-17-2 hydrochloride impairs metastatic seeding and colonization of breast cancer cells.

HY-13738A

Raloxifene hydrochloride Keoxifene hydrochloride; LY156758; LY139481 hydrochloride	Estrogen Receptor/ERR Autophagy	Endocrinology Cancer
Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue.

HY-N2585

Isodeoxyelephantopin	Reactive Oxygen Species NF-κB Autophagy	Cancer
Isodeoxyelephantopin is a sesquiterpene lactone isolated from Elephantopus scaber. Isodeoxyelephantopin induces ROS generation, suppresses NF-κB activation. Isodeoxyelephantopin also modulates LncRNA expression and exhibit activities against breast cancer.

HY-112596A

H3B-6545 hydrochloride	Estrogen Receptor/ERR	Cancer
H3B-6545 hydrochloride is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer.

HY-N0770

Isoliensinine	Apoptosis	Cancer Inflammation/Immunology
Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells.

HY-N6990

Anhydrosecoisolariciresinol	Others	Cancer
Anhydrosecoisolariciresinol is from the flower of Wedelia biflora, has anti-tumor activities. Anhydrosecoisolariciresinol decreases the growth of human breast cancer MCF-7 and MDA-MB-231 cell lines.

HY-112596

H3B-6545	Estrogen Receptor/ERR	Cancer
H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer.

HY-N2028

Demethylwedelolactone	Others	Cancer
Demethylwedelolactone is a naturally occurring coumestan isolated from Eclipta alba. Demethylwedelolactone is a potent trypsin inhibitor with an IC₅₀ of 3.0 μM. Demethylwedelolactone suppresses cell motility and cell invasion of breast cancer cell.

HY-129578

Asperphenamate	Autophagy Cathepsin	Cancer Infection Inflammation/Immunology
Asperphenamate, a fungal metabolite of Aspergillus flatiipes with anti-cancer effect, exhibits IC₅₀ values of 92.3 μM, 96.5 μM and 97.9 μM in T47D, MDA-MB-231 and HL-60 cells, respectively.

HY-P2246

JTP10-△-TATi TFA
JNK Cancer

JTP10-△-TATi TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.
HY-P2247

JTP10-△-R9 TFA
JNK Cancer

JTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.

HY-50767

Palbociclib PD 0332991	CDK	Cancer
Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research.

HY-N1513

Ganoderic acid H	Others	Cancer
Ganoderic acid H is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderic acid H suppresses growth and invasive behavior of breast cancer cells through the inhibition of transcription factors AP-1 and NF-kappaB signaling.

HY-B0723

Ospemifene FC-1271a	Estrogen Receptor/ERR	Cancer
Ospemifene is a non-estrogen selective estrogen receptor modulator (SERM), with K_is of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene can be used for the research of vaginal atrophy and breast cancer.

HY-119377

UPGL00004	Glutaminase	Cancer
UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC₅₀=29 nM; K_d=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines.

HY-112721

FDI-6	Others	Cancer
FDI-6 is an inhibitor of FOXM1. FDI-6 binds directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation.

HY-50767A

Palbociclib monohydrochloride PD 0332991 monohydrochloride	CDK	Cancer
Palbociclib (PD 0332991) monohydrochloride is a highly selective CDK4/6 inhibitor with IC₅₀s of 11 nM and 16 nM, respectively. Palbociclib monohydrochloride has the potential for ER-positive and HER2-negative breast cancer research.

HY-N0431

Astragaloside IV	MMP ERK JNK	Cancer
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

HY-104064

1A-116	Ras	Cancer
1A-116 is a Rac1 inhibitor, with antitumoral and antimetastatic effects in several types of cancer, such as breast cancer. 1A-116 prevents Rac1-regulated processes involved in the primary tumorigenesis and metastastic processes .

HY-19753

KS176	BCRP	Cancer
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter (IC50 values are 0.59 and 1.39 μM in Pheo A and Hoechst 33342 assays respectively). Displays no inhibitory activity against P-gp or MRP1.

HY-13593

Chlorambucil CB-1348; WR-139013	DNA Alkylator/Crosslinker	Cancer
Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease.

HY-13632

Exemestane FCE 24304; EXE	Aromatase	Cancer Endocrinology
Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research.

HY-133737

PROTAC BRD4 Degrader-5	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-5 is a PROTAC-based BRD4 degrader. PROTAC BRD4 Degrader-5 can potent degrade BRD4 in HER2 positive and negative breast cancer cell lines.

HY-N0036

Costunolide (+)-Costunolide; Costus lactone	Apoptosis Endogenous Metabolite	Cancer
Costunolide ((+)-Costunolide) is a naturally occurring sesquiterpene lactone, with antioxidative, anti-inflammatory, antiallergic, bone remodeling, neuroprotective, hair growth promoting, anticancer, and antidiabetic properties. Costunolide can induce cell cycle arrest and apoptosis on breast cancer cells.

HY-W040270

Amino-PEG10-amine	PROTAC Linker	Cancer
Amino-PEG10-amine, a PEG-based PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.

HY-116494

ML753286	BCRP	Cancer
ML753286 is an orally active and selective *BCRP (Breast* cancer resistance protein) inhibitor with an IC₅₀** of 0.6 μM. ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions, and is stable in plasma cross species.

HY-N3354

Lupiwighteone	Apoptosis	Cancer
Lupiwighteone is an isoflavone present widely in wild-growing plants, with antioxidant, antimicrobial and anticancer effects. Lupiwighteone induces caspase-dependent and -independent apoptosis on human breast cancer cells via inhibiting PI3K/Akt/mTOR pathway.

HY-130411

Amino-PEG11-amine	PROTAC Linker	Cancer
Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.

HY-13556

Arzoxifene LY353381; SERM III	Estrogen Receptor/ERR	Metabolic Disease
Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator with a fixed ring structure similar to raloxifene. Arzoxifene has minimal side effects with powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile.

HY-101567

BMS-986158	Epigenetic Reader Domain	Cancer
BMS-986158 is a potent BET inhibitor with IC₅₀s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively.

HY-119653

AZ9482
PARP Cancer

AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively.

HY-100544

FLLL32	STAT JAK Apoptosis	Cancer
FLLL32, a synthetic analog of curcumina, is a JAK2/STAT3 dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.

HY-N6797

Meleagrin	Bacterial c-Met/HGFR Antibiotic	Cancer Infection
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor. Meleagrin is a lead c-Met inhibitory entity useful for the control of c-Met-dependent metastatic and invasive breast malignancies.

HY-12762

QS11	Others	Cancer
QS11 is an inhibitor of ARFGAP1 (ADP-ribosylation factor GTPase-activating protein 1), with an EC₅₀ of 1.5 µM. QS11 modulates Wnt/β-catenin signaling through an effect on protein trafficking. QS11 inhibits migration of ARFGAP overexpressing breast cancer cells.

HY-P9921

Trastuzumab emtansine Ado-Trastuzumab emtansine; PRO132365; T-DM 1	Antibody-Drug Conjugate (ADC) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer.

HY-106376A

L-Buthionine-(S,R)-sulfoximine L-Buthionine sulfoximine; L-BSO	Ferroptosis	Cancer
L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC₅₀ value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.

HY-50767S

Palbociclib D8 PD 0332991 D8	CDK	Cancer
Palbociclib D8 (PD 0332991 D8) is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research.

HY-N5011

5,7-Dimethoxyflavone	Cytochrome P450	Cancer Inflammation/Immunology
5,7-Dimethoxyflavone is one of the major components of Kaempferia parviflora, has anti-obesity, anti-inflammatory, and antineoplastic effects. 5,7-Dimethoxyflavone inhibits cytochrome P450 (CYP) 3As. 5,7-Dimethoxyflavone is also a potent Breast Cancer Resistance Protein (BCRP) inhibitor.

HY-103489

PI-273	PI4K Apoptosis	Cancer
PI-273 is a first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC₅₀ of 0.47 μM. PI-273 can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.

HY-111550

Bragsin2	Others	Cancer
Bragsin2 is a potent, selective and noncompetitive nucleotide exchange factor BRAG2 inhibitor, with an IC₅₀ of 3 μM. Bragsin2 binds at the interface between the PH domain of BRAG2 and the lipid bilayer, leads BRAG2 unable to activate lipidated Arf GTPase. Bragsin2 affects breast cancer stem cells.

HY-14248S

Letrozole-d4	Aromatase Autophagy	Cancer
Letrozole-d4 (CGS 20267-d4) is the deuterium labeled Letrozole. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC₅₀ of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer.

HY-19992

3-Bromopyruvic acid Bromopyruvic acid; Hexokinase II Inhibitor II, 3-BP	Hexokinase Apoptosis Autophagy	Cancer
3-Bromopyruvate (Bromopyruvic acid) is an analogue of pyruvate and a potent hexokinase (HK)-II inhibitor with high tumor selectivity. 3-Bromopyruvate inhibits cell growth and induces apoptosis through interfering with glycolysis. 3-Bromopyruvate induces autophagy by stimulating ROS formation in breast cancer cells. Antimicrobial activities.

HY-10293

Aderbasib INCB007839; INCB7839	MMP	Cancer
Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2⁺ breast cancer, gliomas, et al.

HY-124909

(6R)-FR054
Apoptosis Cancer

(6R)-FR054 is a less active isomer of FR054.

HY-118916

FTI-2148	Farnesyl Transferase	Cancer
FTI-2148 is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC₅₀s of 1.4 nM and 1.7 μM, respectively.

HY-14971

(E)-Akt inhibitor-IV
(E)-AKTIV
Akt Cancer

(E)-Akt inhibitor-IV ((E)-AKTIV) is a PI3K-Akt inhibitor, with potent cytotoxic.
HY-N2331

Proscillaridin A
Topoisomerase Cancer

Proscillaridin A is a potent poison of topoisomerase I/II activity with IC₅₀ values of 30 nM and 100 nM, respectively.

HY-135309

PROTAC ER Degrader-4	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-4 is a PROATC estrogen receptor (ER) degrader, binding to ER with an IC50 of 0.8 nM. PROTAC ER Degrader-4 induces ER degradation in MCF-7 cells with an IC₅₀ of 0.3 nM.

HY-124674A

CCT365623 hydrochloride	Monoamine Oxidase EGFR Akt TGF-beta/Smad	Cancer
CCT365623 hydrochloride is an orally active lysyl oxidase (LOX) inhibitor, with an IC₅₀ of 0.89 μM. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is extremely well tolerated, and has good pharmacokinetic properties.

HY-134886

PD-1-IN-24
PD-1/PD-L1 Cancer

PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor.

HY-15176

Pyridostatin RR82	G-quadruplex	Cancer
Pyridostatin (RR82) is a G-quadruplex DNA stabilizing agent (K_d=490 nM). Pyridostatin promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin targets the proto-oncogene Src. Pyridostatin reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells.

HY-106376C

L-Buthionine-(S,R)-sulfoximine hydrochloride L-Buthionine sulfoximine hydrochloride; L-BSO hydrochloride	Ferroptosis	Cancer Metabolic Disease
L-Buthionine-(S,R)-sulfoximine hydrochloride is a cell-permeable, potent, fast acting, orally active and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC₅₀ value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.

HY-128588

STAT3-IN-3	STAT Apoptosis	Cancer
STAT3-IN-3 is a potent and selective inhibitor of signal transducer and activator of transcription 3 (STAT3), with anti-proliferative activity. STAT3-IN-3 induces apoptosis in breast cancer cells. STAT3-IN-3 acts as a promising mitochondria-targeting STAT3 inhibitor for cancer research.

HY-15176A

Pyridostatin hydrochloride RR82 hydrochloride	G-quadruplex	Cancer
Pyridostatin (RR82) hydrochloride is a G-quadruplex DNA stabilizing agent (K_d=490 nM). Pyridostatin hydrochloride promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin hydrochloride targets the proto-oncogene Src. Pyridostatin hydrochloride reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells.

HY-132173

GL0388	Bcl-2 Family	Cancer
GL0388 is a Bax activator that results in Bax insertion into mitochondrial membrane. GL0388 shows antiproliferative activities against various cancer cells, with IC₅₀s of 0.299-1.57 μM. GL0388 activates Bax and induce Bax-mediated apoptosis. GL0388 suppresses breast cancer xenograft tumor growth in vivo.

HY-N0587

Demethylzeylasteral	Apoptosis	Cancer Inflammation/Immunology
Demethylzeylasteral is a triterpene compound isolated from Tripterygium wilfordii Hook F, with anti-inflammatory, immunosuppressive and anti-tumor activities. Demethylzeylasteral can significantly alleviates atherosclerosis (AS). Demethylzeylasteral inhibits triple-negative breast cancer invasion by blocking the canonical and non-canonical TGF-β signaling pathways.

HY-16231

GGTI-2418	ROS Apoptosis	Cancer
GGTI-2418 is a highly potent, competitive, and selective geranylgeranyltransferase I (GGTase I) inhibitor. GGTI-2418 inhibits GGTase I and FTase activities with IC₅₀s of 9.5 nM and 53 μM, respectively. GGTI-2418 also increases p27(Kip1) and induces significant regression of breast tumors.

HY-N0331

Ziyuglycoside I	MDM-2/p53 Apoptosis	Cancer
Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics. Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential drug candidate for treating triple-negative breast cancer (TNBC).

HY-114169

WRG-28	Discoidin Domain Receptor	Cancer
WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor with an IC₅₀ of 230 nM. WRG-28 uniquely inhibits receptor-ligand interactions via allosteric modulation of the receptor. WRG-28 inhibits tumor invasion and migration, as well as tumor-supporting roles of the stroma, and inhibits metastatic breast tumor cell colonization in the lungs by targeting DDR2.

HY-100012

CBR-5884	Others	Cancer
CBR-5884 is an active, selective inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC₅₀ of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis.

HY-137742

SBP-7455	ULK Autophagy	Cancer
SBP-7455 is a potent, high affinity and orally active dual ULK1/ULK2 autophagy inhibitor with IC₅₀s of 13 nM and 476 nM in the ADP-Glo assays, respectively. SBP-7455 potently inhibits ULK1/2 enzymatic activity and can be used for triple-negative breast cancer (TNBC) research.

HY-12098

Verubulin hydrochloride MPC-6827 hydrochloride	Microtubule/Tubulin	Cancer
Verubulin hydrochloride (MPC-6827 hydrochloride) is a blood brain barrier permeable microtubule-disrupting agent, with potent and broad-spectrum in vitro and in vivo cytotoxic activities. Verubulin hydrochloride (MPC-6827 hydrochloride) exhibits potent anticancer activity in human MX-1 breast and other mouse xenograft cancer models. Verubulin hydrochloride (MPC 6827 hydrochloride) is a promising candidate for the treatment of multiple cancer types.

HY-125374

Larotaxel XRP9881	Apoptosis	Cancer
Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel.

HY-N1440

Koumine	Others	Cancer Inflammation/Immunology
Koumine is an alkaloid separated from Gelsemium elegans, shows potent anti-tumor activity. Koumine up-regulates the Bax/Bcl-2 ratio and caspase-3 expression in human breast cancer cells. Koumine has anxiolytic, antistress, antipsoriatic, and analgesic activities, protects against the development of arthritis in Rheumatoid arthritis (RA) animal models.

HY-115672

KS15	Others	Cancer
KS15 is an inhibitor of the interactions between cryptochromes (CRYs: CRY1 and CRY2) and the CLOCK:BMAL1 heterodimer. KS15 impairs the feedback actions of CRYs on E-box-dependent transcription (EC₅₀=4.9 μM) by CLOCK:BMAL1 heterodimer, an indispensable transcriptional regulator of the mammalian circadian clock. Anti-proliferative activity.

HY-20403

PF-562271 hydrochloride
FAK Pyk2 Cancer

PF-562271 hydrochloride is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC₅₀s of 1.5 nM and 13 nM, respectively.

HY-130798

(S,R,S)-AHPC-amido-C5-acid	E3 Ligase Ligand-Linker Conjugate	Cancer
(S,R,S)-AHPC-amido-C5-acid incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-amido-C5-acid can be used to design XY028-133 (HY-129180).

HY-10459

PF-562271
FAK Pyk2 Cancer

PF-562271 is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC₅₀s of 1.5 nM and 13 nM, respectively.

HY-10127

Barasertib AZD1152	Aurora Kinase Apoptosis	Cancer
Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells.

HY-N8207

Gypenoside LI
Apoptosis MicroRNA Cancer

Gypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration.

HY-100574C

D-Cl-amidine	Protein Arginine Deiminase Apoptosis	Cancer Inflammation/Immunology
D-Cl-amidine is a potent and highly selective PAD1 inhibitor. D-Cl-amidine is well-torelated with no significant toxicity.

HY-114668

Camptothecin-20(S)-O-propionate Camptothecin-20-O-propionate	Topoisomerase	Cancer
Camptothecin-20(S)-O-propionate (CZ48), the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate (CZ48) is a topoisomerase-Ι inhibitor.

HY-16069A

Tucatinib hemiethanolate Irbinitinib hemiethanolate; ARRY-380 hemiethanolate; ONT-380 hemiethanolate	EGFR	Cancer
Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC₅₀ of 8 nM.

HY-10126

Barasertib-HQPA AZD2811; INH-34; AZD1152-HQPA	Aurora Kinase Apoptosis	Cancer
Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells.

HY-137450

Senaparib IMP4297	PARP	Cancer
Senaparib (IMP4297) is a highly potent, selective and orally active PARP1/2 inhibitor. Senaparib (IMP4297) exhibits strong antitumor activity in animal models.

HY-14171S

Bexarotene D4 LGD1069 D4	RAR/RXR Autophagy	Cancer
Bexarotene D4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma.

HY-128600

ERD-308	PROTACs Estrogen Receptor/ERR	Cancer
ERD-308 is a highly potent PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC₅₀ (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively).

HY-15176B

Pyridostatin TFA RR82 TFA	G-quadruplex	Cancer
Pyridostatin (RR82) TFA is a G-quadruplex DNA stabilizing agent (K_d=490 nM). Pyridostatin TFA promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin TFA targets the proto-oncogene Src. Pyridostatin TFA reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells.

HY-138298

Trastuzumab deruxtecan DS-8201; DS-8201a	Antibody-Drug Conjugate (ADC) EGFR	Cancer
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.

HY-130250

SR-4835	CDK Apoptosis	Cancer
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC₅₀=99 nM, K_d=98 nM; CDK13: K_d=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death.

HY-16560

Camptothecin Campathecin; (S)-(+)-Camptothecin; CPT	Topoisomerase ADC Cytotoxin MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Cancer Infection
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.

HY-N6972

Cepharanthine	HIV Autophagy Apoptosis	Cancer Infection Inflammation/Immunology
Cepharanthine is an alkaloid derived from Stephania cepharantha Hayata, with possesses anti-inflammatory and antioxidative activities. Cepharanthine attenuates muscle and kidney injuries induced by limb ischemia/reperfusion (I/R). Cepharanthine induces autophagy, apoptosis and cell cycle arrest in breast cancer cells. Cepharanthine inhibits the HIV-1 entry process by reducing plasma membrane fluidity.

HY-N0411

β-Carotene Provitamin A; beta-Carotene	Endogenous Metabolite ROS Apoptosis	Cancer Metabolic Disease
β-Carotene (Provitamin A), a carotenoid compound, is a naturally-occurring vitamin A precursor. β-Carotene is a modulator of reactive oxygen species (ROS), with antioxidant and antiinflammatory activities. β-Carotene may serve as an antioxidant or as a prooxidant, depending on its intrinsic properties as well as on the redox potential of the biological environment in which it acts. β-Carotene induces breast cancer cells apoptosis, with anticancer activities.

HY-13072

Cenisertib AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia.

HY-103712A

Samuraciclib hydrochloride CT7001 hydrochloride; ICEC0942 hydrochloride	CDK Apoptosis	Cancer
Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC₅₀ of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects.

HY-103712B

Samuraciclib trihydrochloride CT7001 trihydrochloride; ICEC0942 trihydrochloride	CDK Apoptosis	Cancer
Samuraciclib (CT7001) trihydrochloride is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC₅₀ of 41 nM. Samuraciclib trihydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC₅₀ of 578 nM), CDK5 and CDK9, respectively. Samuraciclib trihydrochloride inhibits the growth of breast cancer cell lines with GI₅₀ values between 0.2-0.3 µM. Samuraciclib trihydrochloride has anti-tumor effects.

HY-10262

BMS-536924	IGF-1R Insulin Receptor Apoptosis	Cancer Endocrinology
BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC₅₀s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity.

HY-N3710

Dehydrocrenatidine Kumujian G; O-Methylpicrasidine I	JAK Apoptosis	Cancer Neurological Disease
Dehydrocrenatidine, a natural alkaloid, is a specific JAK inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain.

HY-N2025

Oroxin A	PPAR Glucosidase	Metabolic Disease
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity. Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence.

HY-141551

GNE-274	Estrogen Receptor/ERR	Cancer
GNE-274 is a non-degrader that is structurally related to GDC-0927 (ER degrader). GNE-274 does not induce ER turnover and functions as a partial ER agonist in breast cancer cell lines. GNE-274 increase chromatin accessibility at ER-DNA binding sites, while GDC-0927 do not. GNE-274 is a potent inhibitor of ER-ligand binding domain (LBD). GNE-274 can be used for cancer research.

HY-76474

BAY 61-3606	Syk Apoptosis	Cancer Inflammation/Immunology
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a K_i of 7.5 nM and an IC₅₀ of 10 nM. BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 induces a large decrease of Syk phosphorylation in K-rn cell lysates. Bay 61-3606 sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.

HY-14985

BAY 61-3606 dihydrochloride	Syk Apoptosis	Inflammation/Immunology Cancer
BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a K_i of 7.5 nM an IC₅₀ of 10 nM. BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates. Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.

HY-15843

MIR96-IN-1	MicroRNA Apoptosis	Cancer
MIR96-IN-1 targets the Drosha site in the miR-96 (miRNA-96, microRNA-96) hairpin precursor, inhibiting its biogenesis, derepressing downstream targets, and triggering apoptosis in breast cancer cells. MIR96-IN-1 binds to RNAs with K_ds of 1.3, 9.4, 3.4, 1.3 and 7.4 μM for RNA1, RNA2, RNA3, RNA4 and RNA5, respectively.

HY-16106

Talazoparib BMN-673; LT-673	PARP	Cancer
Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.

HY-N6877

Purpurogallin carboxylic acid	Others	Cancer
Purpurogallin carboxylic acid, isolated from Macleaya microcarpa (Maxim.) Fedde, is an oxidation product of gallic acid in fermented tea. Purpurogallin carboxylic acid has anti-cancer activity.

HY-136578

RP101988	LPL Receptor Drug Metabolite	Cancer Inflammation/Immunology
RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC₅₀s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely.

HY-N8405

Isolimonexic acid
Aromatase Cancer

Isolimonexic acid is a limonoid isolated from lemon (Citrus lemon L. Burm) seed, has anti-cancer and anti-aromatase (IC₅₀=25.60 μM) properties.

HY-P3245

HXR9	Apoptosis	Cancer
HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells.

HY-15861

Targapremir-210 TGP-210	MicroRNA Apoptosis	Cancer
Targapremir-210 (TGP-210) is a potent and selective miR-210 (miRNA-210, microRNA-210) inhibitor. Targapremir-210 inhibits pre-miR-210 processing with high binding affinity (K_d~200 nM).

HY-N0183

Formononetin Biochanin B; Flavosil; Formononetol	FGFR Apoptosis	Cancer Cardiovascular Disease
Formononetin is a potent FGFR2 inhibitor with an IC₅₀ of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth.

HY-15338

TG003
CDK Cancer

TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC₅₀ values of 20 and 15 nM, respectively.

HY-15338A

(E/Z)-TG003	CDK	Cancer
(E/Z)-TG003 is a racemic compound of (Z)-TG003 and (E)-TG003. (Z)-TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC₅₀ values of 20 and 15 nM, respectively.

HY-135793

Macropa-NH2 diester	Others	Cancer
Macropa-NH2 diester is a compound can be used for imaging during the investigation of cancer. Macropa-NH2 diester is compound 210 extracted from patent WO2018187631.

HY-18758

IN-1130	TGF-β Receptor	Cancer Inflammation/Immunology
IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀=36 nM) and p38α mitogen-activated protein kinase (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis.

HY-12302

Kenpaullone 9-Bromopaullone; NSC-664704	CDK GSK-3	Cancer
Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC₅₀s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC₅₀s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.

HY-N0411S

β-Carotene-d10	Endogenous Metabolite ROS Apoptosis	Cancer Metabolic Disease
β-Carotene-d10 (Provitamin A-d1) is the deuterium labeled β-Carotene. β-Carotene (Provitamin A), a carotenoid compound, is a naturally-occurring vitamin A precursor. β-Carotene is a modulator of reactive oxygen species (ROS), with antioxidant and antiinflammatory activities. β-Carotene may serve as an antioxidant or as a prooxidant, depending on its intrinsic properties as well as on the redox potential of the biological environment in which it acts. β-Carotene induces breast cancer cells apoptosis, with anticancer activities.

HY-104040

MKC8866	IRE1	Cancer
MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC₅₀ of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC₅₀ of 0.52 μM and unstresses RPMI 8226 cells with an IC₅₀ of 0.14 μM. MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth.

HY-125916

Pseurotin A	Others	Cancer
Pseurotin A, a secondary metabolite of Aspergillus and other fungi, is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC₅₀=3.6 μM). Antitumor activity.

HY-16023A

Acolbifene EM-652; SCH 57068	Estrogen Receptor/ERR	Cancer
Acolbifene (EM-652), the active metabolite of EM800, is an orally active pure antiestrogen and selective estrogen receptor antagonist. Acolbifene (EM-652) inhibits estradiol (E2)-induced transcriptional activity of ERα (IC₅₀ = 2 nM) and ERβ (IC₅₀ = 0.4 nM). Acolbifene (EM-652) possesses potent and pure anticarcinogenic properties.

HY-19313

LLY-507	Histone Methyltransferase	Cancer
LLY-507 is a potent and selective inhibitor of protein-lysine methyltransferase SMYD2. LLY-507 potently inhibits the ability of SMYD2 to methylate p53 peptide with an IC₅₀ <15 nM. LLY-507 serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.

HY-121149

Droloxifene 3-Hydroxytamoxifen	Estrogen Receptor/ERR Apoptosis	Cancer
Droloxifene, a Tamoxifen derivative, is an orally active and selective estrogen receptor modulator. Droloxifene shows antiestrogenic and anti-implantation effects. Droloxifene induces p53 expression and apoptosis in MCF-7 cells. Droloxifene prevents bone loss in ovariectomized rats .

HY-133124

PARP/PI3K-IN-1	PARP PI3K Apoptosis	Cancer
PARP/PI3K-IN-1 (compound 15) is a potent PARP/PI3K inhibitor with pIC₅₀ values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases.

HY-112626

CDK12-IN-2	CDK	Cancer
CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC₅₀=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12.

HY-102087

JPM-OEt	Cathepsin	Cancer
JPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity.

HY-101089

RHPS4
Telomerase Apoptosis Cancer

RHPS4 is a potent telomerase inhibitor (IC₅₀ = 0.33 μM). RHPS4 is a DNA damage inducer.

HY-110201

Estrogen receptor modulator 1	Estrogen Receptor/ERR	Cancer
Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC₅₀ of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors.

HY-N2058

Neogambogic acid	Bacterial Apoptosis	Cancer Infection
Neogambogic acid, an active ingredient in garcinia, induces apoptosis and has anticancer effect. Neogambogic acid has significant inhibitory activity toward methicillin-resistant Staphylococcus aureus (MRSA).

HY-16023

Acolbifene hydrochloride EM-652 hydrochloride; SCH 57068 hydrochloride	Estrogen Receptor/ERR	Cancer
Acolbifene (EM-652) hydrochloride, an active metabolite of EM800, is an orally active, cancer-preventing selective estrogen receptor modulator (SERM). Acolbifene (EM-652) hydrochloride inhibits estradiol (E2)-induced transcriptional activity of ERα (IC₅₀=2 nM) and ERβ (IC₅₀=0.4 nM). Acolbifene (EM-652) hydrochloride exerts a potent and pure antiestrogenic action in the mammary gland and uterus. Anticarcinogenic properties.

HY-N0104

Curcumol (-)-Curcumol	Apoptosis	Cancer
Curcumol ((-)-Curcumol), a bioactive sesquiterpenoid, possesses numerous pharmacological activities like anticancer, antimicrobial, antifungal, antiviral, and antiinflammatory. Curcumol is a potent inducer of apoptosis in numerous cancer cells via targeting key signaling pathways as MAPK/ERK, PI3K/Akt and NF-κB which are generally deregulated in several cancers.

HY-10619

Niraparib MK-4827	PARP Apoptosis	Cancer
Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC₅₀s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.

HY-10619A

Niraparib hydrochloride MK-4827 hydrochloride	PARP Apoptosis	Cancer
Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC₅₀s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.

HY-15244

Alpelisib BYL-719	PI3K	Cancer
Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC₅₀s of 5/250/290/1200 nM, respectively. Antineoplastic activity.

HY-100789

ON1231320	Polo-like Kinase (PLK) Apoptosis	Cancer
ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC₅₀ of 0.31 µM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity.

HY-10358

MK-2206 dihydrochloride MK-2206 (2HCl)	Akt Autophagy Apoptosis	Cancer
MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active allosteric AKT inhibitor with IC₅₀s of 5 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy.

HY-110147A

SSM3 tetraTFA	Others	Infection
SSM3 tetraTFA is a potent synthetic furin inhibitor with an EC₅₀ and a K_i of 54 nM and 12 nM, respectively. SSM3 tetraTFA is able to block furin-dependent cell surface processing of anthrax protective antigen-83 in vitro.

HY-15888

PTC-209	Autophagy	Cancer
PTC-209 is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment.

HY-15888A

PTC-209 hydrobromide	Autophagy	Cancer
PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment.

HY-136270

Gartisertib VX-803; M4344; ATR inhibitor 2	ATM/ATR	Cancer
Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity.

HY-N7678

Gypenoside LXXV	Others	Cancer
Gypenoside LXXV, isolated from Gynostemma pentaphyllum, is one of the deglycosylated shapes of ginsenoside Rb1. Gypenoside LXXV significantly reduces cancer cell viability and displays an anti-cancer effect.

HY-10619B

Niraparib tosylate MK-4827 tosylate	PARP Apoptosis	Cancer
Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC₅₀ of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.

HY-139058

23-epi-26-Deoxyactein
27-Deoxyactein
Others Cancer Metabolic Disease

23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.

HY-17547

NMS-E973	HSP	Cancer
NMS-E973 is a potent and selective inhibitor of HSP90. NMS-E973 binds to the ATP binding site of Hsp90α with a DC₅₀ of <10 nM. NMS-E973 is able to cross the blood-brain barrier (BBB). Antitumor efficacy.

HY-15319

AMG 487	CXCR	Cancer Inflammation/Immunology Endocrinology
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC₅₀s of 8.0 and 8.2 nM, respectively.

HY-19928A

Vactosertib Hydrochloride EW-7197 Hydrochloride; TEW-7197 Hydrochloride	TGF-β Receptor	Cancer
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect.

HY-13591

Piclidenoson IB-MECA; CF-101	Adenosine Receptor Apoptosis	Cancer Inflammation/Immunology
Piclidenoson (IB-MECA) is a first-in-class, orally active and selective A3 adenosine receptor (A3AR) agonist. Piclidenoson exhibits antiproliferative effect and induces apoptosis in different cancer cell types like melanoma, leukemia. Piclidenoson can be used for the research of autoimmune inflammatory diseases and COVID-19.

HY-100501

M2698 MSC2363318A	Ribosomal S6 Kinase (RSK) Akt	Cancer
M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC₅₀s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity.

HY-16931

SMIFH2
Others Cancer

SMIFH2 is a formin specific inhibitor. SMIFH2 inhibits actin polymerization by Formins and affects the actin cytoskeleton.

HY-N1506

Ganodermanontriol	Others	Cancer
Ganodermanontriol, a sterol isolated from Ganoderma lucidum, induces anti-inflammatory activity in tert-butyl hydroperoxide (t-BHP)-damaged hepatic cells through the expression of HO-1. Ganodermanontriol exhibits hepatoprotective activity.

HY-13757AS

Tamoxifen-d5 ICI 47699-d5; (Z)-Tamoxifen-d5; trans-Tamoxifen-d5	Estrogen Receptor/ERR HSP Autophagy Apoptosis	Cancer
Tamoxifen-d5 (ICI 47699-d5) is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity.

HY-136406

Bongkrekic acid	ATP Synthase	Cancer Infection
Bongkrekic acid is a mitochondrial toxin secreted by the bacteria Pseudomonas cocovenenans. Bongkrekic acid specific ligand for mitochondrial adenine nucleotide translocase (ANT) rather than the electron transport chain. Bongkrekic acid has to cross the mitochondrial inner membrane to produce its inhibitory effect on ADP/ATP transport.

HY-15319A

(±)-AMG 487	CXCR	Cancer
(±)-AMG 487 is a racemate of AMG 487. AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC₅₀s of 8.0 and 8.2 nM, respectively.

HY-19928

Vactosertib EW-7197; TEW-7197	TGF-β Receptor	Cancer
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect.

HY-B0846

Dimethomorph	Fungal Androgen Receptor	Infection
Dimethomorph is a morpholine fungicide that inhibits fungal cell wall formation. Dimethomorph inhibits mycelial growth of the oomycete fungi, *P. citrophthora, P. parasitica, P. capsici, and P. infestans* (EC₅₀s=0.1, 0.38, <0.1, and 0.16-0.3 µg/mL, respectively), but is less active against the green algae species C. vulgaris or S. obliquus in vitro (EC₅₀s=47.46 and 44.87 µg/mL, respectively). Dimethomorph inhibits androgen receptor (AR) activity in a reporter assay in MDA-kb2 human breast cancer cells but not in a yeast antiandrogen screen (IC₂₀s=0.263 and 38.5 µM, respectively).

HY-P2076

Dusquetide SGX942	Bacterial	Cancer Infection
Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

HY-N2521

Tetramethylcurcumin FLLL31	STAT Apoptosis	Cancer Inflammation/Immunology
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects.

HY-106662

Chloroquinoxaline sulfonamide Chloroquinoxaline; NSC-339004	Topoisomerase Parasite	Cancer Infection
Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle. Antitumor activity.

HY-N0484

Liensinine	Autophagy Mitophagy Apoptosis	Cancer Cardiovascular Disease
Liensinine is an autophagy/mitophagy inhibitor. Liensinine, a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn, has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc.

HY-12248A

Telaglenastat hydrochloride CB-839 hydrochloride	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy and has antitumor activity.

HY-116852

Thiocolchicine	Microtubule/Tubulin Apoptosis	Cancer
Thiocolchicine, a derivative modified in the C Ring of Colchicine (HY-16569) with enhanced biological properties. Thiocolchicine is a potent inhibitor of tubulin polymerization (IC₅₀=2.5 µM) and competitively binds to tubulin with a K_i of 0.7 µM. Thiocolchicine induces cell apoptosis. Thiocolchicine can be used as an ADC cytotoxin in ADC technology.

HY-12248

Telaglenastat CB-839	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inudces autophagy and has antitumor activity.

HY-P2076A

Dusquetide TFA SGX942 TFA	Bacterial	Cancer Infection
Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

HY-122181A

OTS186935 trihydrochloride	Histone Methyltransferase	Cancer
OTS186935 trihydrochloride is a protein methyltransferase SUV39H2 inhibitor with an IC₅₀ of 6.49 nM. OTS186935 trihydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS186935 trihydrochloride regulates the production of γ-H2AX in cancer cells.

HY-135236

OXFBD04	Epigenetic Reader Domain	Cancer
OXFBD04 is a potent and selective BRD4 inhibitor with an IC₅₀ of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity.

HY-122181B

OTS186935 hydrochloride	Histone Methyltransferase	Cancer
OTS186935 hydrochloride is a potent protein methyltransferase SUV39H2 inhibitor with an IC₅₀ of 6.49 nM. OTS186935 hydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 hydrochloride regulates the production of γ-H2AX in cancer cells.

HY-110339

RKI-1447 dihydrochloride	ROCK Apoptosis	Cancer
RKI 1447 dihydrochloride is a potent and selective ROCK inhibitor with IC₅₀s of 14.5 and 6.2 nM for ROCK1 and ROCK2, respectively. RKI 1447 dihydrochloride suppresses colorectal carcinoma cell growth and promotes apoptosis.

HY-10181B

Dasatinib monohydrate BMS-354825 monohydrate	Bcr-Abl Src Autophagy Apoptosis	Cancer
Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC₅₀s of <1.0 nM and 0.5 nM, respectively. Dasatinib monohydrate also induces apoptosis and autophagy.

HY-137605

WSF1-IN-1	Others	Cancer
WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC₅₀ values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively.

HY-128587

Mevociclib SY-1365	CDK	Cancer
Mevociclib (SY-1365) is a potent and first-in-class selective CDK7 inhibitor, with a K_i of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors.

HY-10181A

Dasatinib hydrochloride BMS-354825 hydrochloride	Bcr-Abl Src Autophagy Apoptosis	Cancer
Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC₅₀s of <1.0 nM and 0.5 nM, respectively. Dasatinib hydrochloride also induces apoptosis and autophagy.

HY-122181

OTS186935	Histone Methyltransferase	Cancer
OTS186935 is a potent protein methyltransferase SUV39H2 inhibitor with an IC₅₀ of 6.49 nM. OTS186935 shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 regulates the production of γ-H2AX in cancer cells.

HY-10181

Dasatinib BMS-354825	Bcr-Abl Src Autophagy Apoptosis	Cancer
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC₅₀s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.

HY-P1103

CTCE-9908	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells.

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells.

HY-120118

Metarrestin ML246	DNA/RNA Synthesis	Cancer
Metarrestin (ML246) is an orally active, first-in-class and specific perinucleolar compartment inhibitor. Metarrestin disrupts the nucleolar structure and inhibits RNA polymerase (Pol) I transcription, at least in part by interacting with the translation elongation factor eEF1A2. Metarrestin blocks metastatic development and extends survival in mouse cancer models.

HY-110353

CU-T12-9	Toll-like Receptor (TLR)	Cancer Inflammation/Immunology
CU-T12-9 is a specific TLR1/2 agonist with EC₅₀ of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS.

HY-135849

Catalase	Reactive Oxygen Species	Cancer
Catalase is a key enzyme in the metabolism of H₂O₂ and reactive oxygen species (ROS), and its expression and localization is markedly altered in tumors. Free oxygen radical scavenger.

HY-108333

SB-633825	Others	Cancer Cardiovascular Disease
SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC₅₀s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis.

HY-123611

Supinoxin RX-5902	DNA/RNA Synthesis Apoptosis	Cancer
Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase (P-p68) and a potent first-in-class anti-cancer agent. Supinoxin interacts with Y593 phosphorylated-p68 and attenuates the nuclear shuttling of β-catenin. Supinoxin induces cell apoptosis and inhibits growth of TNBC cancer cell lines with IC₅₀s ranging from 10 nM to 20 nM.

HY-136379

CID44216842 Cdc42-IN-1	Ras	Cancer
CID44216842 (Cdc42-IN-1) is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC₅₀s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively. The EC₅₀s for Cdc42 WT and Cdc42Q61L mutant are 0.3 and 0.5 μM in GDP binding assay, respectively. Use as a molecular probe.

HY-133136

PROTAC BRD4 Degrader-2
PROTACs Epigenetic Reader Domain Cancer

PROTAC BRD4 Degrader-2 is an efficacious PROTAC BRD4 degrader with an IC₅₀ of 14.2 nM against BRD4 BD1.

HY-136241

OT-82	NAMPT	Cancer
OT-82 is a potent, selective and orally active inhibitor of NAMPT. OT-82 is selectively toxic to cells of hematopoietic origin and induces cell death in a NAD⁺ dependent manner. OT-82 is a promising antineoplastic agent for the study of hematological malignancies.

HY-N0171A

Beta-Sitosterol (purity>98%) β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%)	Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
Beta-Sitosterol (purity>98%) is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171B

Beta-Sitosterol (purity>75%) β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%)	Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
Beta-Sitosterol (purity>75%) includes 75% β-sitosterol and 10% campesterol. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>75%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171

Beta-Sitosterol (purity>80%) β-Sitosterol (purity>80%); 22,23-Dihydrostigmasterol (purity>80%)	Endogenous Metabolite Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library

1277 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 1277 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-122878

HS-131	Fluorescent Dyes/Probes
HS-131, a near infrared dye tethered Hsp90 inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers.

HY-107967

Isosulfan blue	Dyes
Isosulfan blue is a blue dye for the identification of lymph vessels during lymphangiography. Isosulfan blueis is used during sentinel lymph node biopsies in breast cancer. Isosulfan blue is possible to have an allergic reaction during breast cancer operations.

Cat. No.	Product Name	Target	Research Area

HY-13673A

Goserelin acetate ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.

HY-P0237

KKI-5
Peptides Cancer

KKI-5 is a specific inhibitor of tissue kallikrein. KKI-5 can attenuate breast cancer cell invasion.
HY-P0237A

KKI-5 (TFA)
Peptides Cancer

KKI-5 (TFA) is a specific inhibitor of tissue kallikrein. KKI-5 (TFA) can attenuate breast cancer cell invasion.
HY-P2246

JTP10-△-TATi TFA
JNK Cancer

JTP10-△-TATi TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.
HY-P2247

JTP10-△-R9 TFA
JNK Cancer

JTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.
HY-P1914

NY-BR-1 p904 (A2)
Peptides Cancer

NY-BR-1 p904 (A2) is an HLA-A2-restricted NY-BR-1 epitope. T-cell clone specific for NY-BR-1 p904 can recognize breast tumor cells expressing NY-BR-1.
HY-P3207A

DLPLTFGGGTK TFA
Peptides Others

DLPLTFGGGTK (TFA) is a surrogate peptide for pembrolizumab identification.

HY-P3212

Allo-aca	Peptides	Cancer
Allo-aca, a leptin peptidomimetic, is a potent, specific leptin receptor antagonist peptide. Allo-aca blocks leptin signaling and action in numerous in vitro and in vivo models.

HY-P3245

HXR9	Apoptosis	Cancer
HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells.

HY-P2076

Dusquetide SGX942	Bacterial	Cancer Infection
Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

HY-P1103

CTCE-9908	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells.

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells.

Cat. No.	Product Name	Target	Research Area

HY-P9907

Trastuzumab Anti-Human HER2, Humanized Antibody	EGFR	Cancer
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9912

Pertuzumab
EGFR Cancer

Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P9921

Trastuzumab emtansine Ado-Trastuzumab emtansine; PRO132365; T-DM 1	Antibody-Drug Conjugate (ADC) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer.

Cat. No.	Product Name	Target	Category

HY-N2547

Steviolbioside	Others	Terpenoids and Glycosides
Steviolbioside is a rare sweetener that exists in stevia rebaudiana leaves. Steviolbioside presents inhibition on several human cancer cells and acts as potential remedy for human breast cancer.

HY-N1823

Pygenic acid A	Apoptosis	Acids and Aldehydes
Pygenic acid A is a natural compound that can be found in Prunella vulgaris. Pygenic acid A induces apoptosis in metastatic breast cancer cells. Pygenic acid A can be used for the research of diabetes, inflammatory diseases, and cancers.

HY-W010248

2-Phenylglycine
DL-α-Phenylglycine
Endogenous Metabolite Acids and Aldehydes

2-Phenylglycine (DL-α-Phenylglycine) is a metabolite in breast milk during the W2 to W4 lactation period.

HY-N3442

Juglanin	JNK Apoptosis Autophagy	Flavonoids
Juglanin, a natural occurring flavonoid, is a JNK acticator, with inflammation and anti-tumor activities. Juglanin can induce apoptosis and autophagy on human breast cancer cells.

HY-N9232

Rutaevin 7-acetate		Natural Products
Rutaevin 7-acetate, a limonoid, has the potential for the research of the growth of estrogen receptor-negative and -positive human breast cancer cells.

HY-N6007

Chrysosplenol D	Apoptosis	Phenols
Chrysosplenol D is a methoxy flavonoid that induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Chrysosplenol D also exhibits anti-inflammatory and moderate antitrypanosomal activities.

HY-N2059

Santalol	Others	Natural Products
Santalol is a mixture of α and β-isomer santalol. α-santalol is isolated from sandalwood oil. α-santalol is a promising anti-cancer agent against cancers such as oral, breast, prostate and skin cancer.

HY-W005288

4-Vinylphenol	Apoptosis Endogenous Metabolite	Phenols
4-Vinylphenol is found in the medicinal herb Hedyotis diffusa Willd, wild rice and is also the metabolite of p-coumaric and ferulic acid by lactic acid bacteria in wine. 4-Vinylphenol induces apoptosis and inhibits blood vessels formation and suppresses invasive breast tumor growth in vivo.

HY-N0595

Genistin Genistine; Genistoside; Genistein 7-O-β-D-glucopyranoside	Estrogen Receptor/ERR Apoptosis	Flavonoids Saccharides and Glycosides
Genistin (Genistine), an isoflavone belonging to the phytoestrogen family, is a potent anti-adipogenic and anti-lipogenic agent. Genistin attenuates cellular growth and promotes apoptotic cell death breast cancer cells through modulation of ERalpha signaling pathway.

HY-120140

Ganoderic acid DM	Apoptosis PI3K	Terpenoids and Glycosides
Ganoderic acid DM, a natural triterpenoid isolated from Ganoderma lucidum, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Ganoderic acid DM as a specific inhibitor of osteoclastogenesis.

HY-N3995

5β-Dihydrocortisol	Apoptosis Drug Metabolite	Steroids
5β-Dihydrocortisol, a metabolite of Cortisol, is a potential mineralocorticoid. 5β-Dihydrocortisol can potentiate glucocorticoid activity in raising the intraocular pressure. 5β-Dihydrocortisol causes breast cancer cell apoptosis.

HY-N8122

24-Methylenecycloartanyl ferulate	Akt	Phenols
24-Methylenecycloartanyl ferulate is a γ-oryzanol compound. 24-Methylenecycloartanyl ferulate promotes parvin-beta expression in human breast cancer cells. 24-Methylenecycloartanyl ferulate is a potential ATP-competitive Akt1 inhibitor (EC₅₀= 33.3μM).

HY-N7695

Physalin B	Apoptosis Autophagy	Natural Products
Physalin B, one of the major active steroidal constituents of Cape gooseberry, induces cell cycle arrest and triggers apoptosis in breast cancer cells through modulating p53-dependent apoptotic pathway. Physalin B inhibits the ubiquitin-proteasome pathway and induces incomplete autophagic response in human colon cancer cells in vitro.

HY-N2098

Obtusifolin	NF-κB	Quinones
Obtusifolin, isolated from the seeds of Cassia obtusifolia, regulates the gene expression and production of MUC5AC mucin in airway epithelial cells via inhibiting NF-kB pathway. Obtusifolin suppresses phthalate esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein.

HY-N6885

Puerarin-4'-O-β-D-glucopyranoside	Others	Flavonoids
Puerarin-4'-O-β-D-glucopyranoside (compound 8) is a isoflavone from Pueraria lobata root (PLR). Puerarin-4'-O-β-D-glucopyranoside has estrogenic activity and anti-proliferation of MCF-7 human breast carcinoma cells.

HY-N2666

5α-Hydroxycostic acid	VEGFR	Terpenoids and Glycosides
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating VEGF/VEGFR2 and Ang2/Tie2 pathways.

HY-N0292

Oleuropein	PPAR Apoptosis Aromatase	Terpenoids and Glycosides
Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity. Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase.

HY-N3032

Xanthatin	Apoptosis VEGFR Lipoxygenase Bacterial	Terpenoids and Glycosides
Xanthatin is isolated from Xanthium strumarium leaves. Xanthatin exhibits strong antitumor activities against a variety of cancer cells through apoptosis persuasion and shows anti-inflammatory activities by inhibiting PGE2 synthesis and 5-lipoxygenase activity. Xanthatin is a potent and orally active inhibitor of VEGFR2 kinase activity with an IC₅₀ of 3.8 μM and prominently blocks the phosphorylation of VEGFR2 at Tyr951 site. Xanthatin inhibits angiogenesis and has the potential for the investigation of breast cancer.

HY-15731

Estetrol	Estrogen Receptor/ERR Endogenous Metabolite	Natural Products
Estetrol, a natural estrogen synthesized exclusively during pregnancy by the human fetal liver, is a selective nuclear estrogen receptor modulator. Estetrol exerts estrogenic actions on the endometrium or the central nervous system but presents antagonistic effects on the breast.

HY-119906

Conglobatin FW-04-806	HSP Apoptosis	Natural Products
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo.

HY-W004307

Octadecanal
Endogenous Metabolite Natural Products

Octadecanal is a long-chain aldehyde, present in both thigh and breast muscle.

HY-14590

Kaempferol Kempferol; Robigenin	Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite	Flavonoids
Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer.

HY-B0412

Estriol Oestriol	Estrogen Receptor/ERR Endogenous Metabolite	Natural Products
Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast cancer cells.

HY-N6820

Iristectorin A
Others Flavonoids Saccharides and Glycosides

Iristectorin A, a natural product from Iris tectorum, has anti-cancer activities in breast cancer.
HY-N6819

Iristectorin B
Others Flavonoids Saccharides and Glycosides

Iristectorin B is an isoflavone from Iris tectorum, has anti-cancer activities in breast cancer.

HY-128553

Antineoplaston A10	Ras Apoptosis Endogenous Metabolite	Natural Products
Antineoplaston A10, a naturally occurring substance in human body, is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.

HY-125848

Ginsenoside F2	Apoptosis Autophagy Endogenous Metabolite	Saccharides and Glycosides Terpenoids and Glycosides
Ginsenoside F2, a metabolite from Ginsenoside Rb1, induces apoptosis accompanied by protective autophagy in breast cancer stem cells.

HY-107309

Scabioside C	Others	Saccharides and Glycosides
Scabioside C is a main triterpenoid saponin for total secondary saponin (TSS). TSS, from A. raddeana, exhibits the potential anti-breast cancer effect.

HY-N8187

Eupalinolide O	Apoptosis	Terpenoids and Glycosides
Eupalinolide O is a sesquiterpene lactone with anticancer activities. Eupalinolide O induces cell apoptosis in human MDA-MB-468 breast cancer cells.

HY-N3755

Dihydroresveratrol	Estrogen Receptor/ERR	Phenols
Dihydroresveratrol, a potent phytoestrogen, is a hormone receptor modulator. Dihydroresveratrol exhibits proliferative effects in androgen-independent prostate and breast cancer cells at picomolar and nanomolar concentrations.

HY-N4010

Iriflophenone
Others Phenols

Iriflophenone, isolated from Aquilaria sinensis, stimulates MCF-7 and T-47D human breast cancer cells proliferation.

HY-N0399

Wogonoside	Autophagy	Flavonoids
Wogonoside, a flavonoid glycoside isolated from Huangqin, possesses anti-inflammatory effects. Wogonoside induces autophagy in breast cancer cells by regulating MAPK-mTOR pathway.

HY-N2483

Hydroprotopine	Others	Alkaloids
Hydroprotopine is a alkaloid from Hypecoum leptocarpumand. Leptopidine can suppress growth and induce cytotoxicity in breast cancer cells and that the cytotoxicity of leptopidine may be related to its inhibitory effect on fatty acid synthase expression.

HY-N2585

Isodeoxyelephantopin	Reactive Oxygen Species NF-κB Autophagy	Terpenoids and Glycosides
Isodeoxyelephantopin is a sesquiterpene lactone isolated from Elephantopus scaber. Isodeoxyelephantopin induces ROS generation, suppresses NF-κB activation. Isodeoxyelephantopin also modulates LncRNA expression and exhibit activities against breast cancer.

HY-N0770

Isoliensinine	Apoptosis	Alkaloids
Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells.

HY-N6990

Anhydrosecoisolariciresinol	Others	Natural Products
Anhydrosecoisolariciresinol is from the flower of Wedelia biflora, has anti-tumor activities. Anhydrosecoisolariciresinol decreases the growth of human breast cancer MCF-7 and MDA-MB-231 cell lines.

HY-N2028

Demethylwedelolactone	Others	Flavonoids
Demethylwedelolactone is a naturally occurring coumestan isolated from Eclipta alba. Demethylwedelolactone is a potent trypsin inhibitor with an IC₅₀ of 3.0 μM. Demethylwedelolactone suppresses cell motility and cell invasion of breast cancer cell.

HY-129578

Asperphenamate	Autophagy Cathepsin	Natural Products
Asperphenamate, a fungal metabolite of Aspergillus flatiipes with anti-cancer effect, exhibits IC₅₀ values of 92.3 μM, 96.5 μM and 97.9 μM in T47D, MDA-MB-231 and HL-60 cells, respectively.

HY-N1513

Ganoderic acid H	Others	Terpenoids and Glycosides
Ganoderic acid H is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderic acid H suppresses growth and invasive behavior of breast cancer cells through the inhibition of transcription factors AP-1 and NF-kappaB signaling.

HY-N0431

Astragaloside IV	MMP ERK JNK	Saccharides and Glycosides Terpenoids and Glycosides
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

HY-N0036

Costunolide (+)-Costunolide; Costus lactone	Apoptosis Endogenous Metabolite	Terpenoids and Glycosides
Costunolide ((+)-Costunolide) is a naturally occurring sesquiterpene lactone, with antioxidative, anti-inflammatory, antiallergic, bone remodeling, neuroprotective, hair growth promoting, anticancer, and antidiabetic properties. Costunolide can induce cell cycle arrest and apoptosis on breast cancer cells.

HY-N3354

Lupiwighteone	Apoptosis	Flavonoids
Lupiwighteone is an isoflavone present widely in wild-growing plants, with antioxidant, antimicrobial and anticancer effects. Lupiwighteone induces caspase-dependent and -independent apoptosis on human breast cancer cells via inhibiting PI3K/Akt/mTOR pathway.

HY-N6797

Meleagrin	Bacterial c-Met/HGFR Antibiotic	Alkaloids
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor. Meleagrin is a lead c-Met inhibitory entity useful for the control of c-Met-dependent metastatic and invasive breast malignancies.

HY-N5011

5,7-Dimethoxyflavone	Cytochrome P450	Flavonoids
5,7-Dimethoxyflavone is one of the major components of Kaempferia parviflora, has anti-obesity, anti-inflammatory, and antineoplastic effects. 5,7-Dimethoxyflavone inhibits cytochrome P450 (CYP) 3As. 5,7-Dimethoxyflavone is also a potent Breast Cancer Resistance Protein (BCRP) inhibitor.

HY-N2331

Proscillaridin A
Topoisomerase Saccharides and Glycosides

Proscillaridin A is a potent poison of topoisomerase I/II activity with IC₅₀ values of 30 nM and 100 nM, respectively.

HY-N0587

Demethylzeylasteral	Apoptosis	Terpenoids and Glycosides
Demethylzeylasteral is a triterpene compound isolated from Tripterygium wilfordii Hook F, with anti-inflammatory, immunosuppressive and anti-tumor activities. Demethylzeylasteral can significantly alleviates atherosclerosis (AS). Demethylzeylasteral inhibits triple-negative breast cancer invasion by blocking the canonical and non-canonical TGF-β signaling pathways.

HY-N0331

Ziyuglycoside I	MDM-2/p53 Apoptosis	Saccharides and Glycosides Terpenoids and Glycosides
Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics. Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential drug candidate for treating triple-negative breast cancer (TNBC).

HY-N1440

Koumine	Others	Alkaloids
Koumine is an alkaloid separated from Gelsemium elegans, shows potent anti-tumor activity. Koumine up-regulates the Bax/Bcl-2 ratio and caspase-3 expression in human breast cancer cells. Koumine has anxiolytic, antistress, antipsoriatic, and analgesic activities, protects against the development of arthritis in Rheumatoid arthritis (RA) animal models.

HY-N8207

Gypenoside LI	Apoptosis MicroRNA	Terpenoids and Glycosides
Gypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration.

HY-16560

Camptothecin Campathecin; (S)-(+)-Camptothecin; CPT	Topoisomerase ADC Cytotoxin MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Alkaloids
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.

HY-N6972

Cepharanthine	HIV Autophagy Apoptosis	Alkaloids
Cepharanthine is an alkaloid derived from Stephania cepharantha Hayata, with possesses anti-inflammatory and antioxidative activities. Cepharanthine attenuates muscle and kidney injuries induced by limb ischemia/reperfusion (I/R). Cepharanthine induces autophagy, apoptosis and cell cycle arrest in breast cancer cells. Cepharanthine inhibits the HIV-1 entry process by reducing plasma membrane fluidity.

HY-N0411

β-Carotene Provitamin A; beta-Carotene	Endogenous Metabolite ROS Apoptosis	Terpenoids and Glycosides
β-Carotene (Provitamin A), a carotenoid compound, is a naturally-occurring vitamin A precursor. β-Carotene is a modulator of reactive oxygen species (ROS), with antioxidant and antiinflammatory activities. β-Carotene may serve as an antioxidant or as a prooxidant, depending on its intrinsic properties as well as on the redox potential of the biological environment in which it acts. β-Carotene induces breast cancer cells apoptosis, with anticancer activities.

HY-N3710

Dehydrocrenatidine Kumujian G; O-Methylpicrasidine I	JAK Apoptosis	Alkaloids
Dehydrocrenatidine, a natural alkaloid, is a specific JAK inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain.

HY-N2025

Oroxin A	PPAR Glucosidase	Flavonoids Saccharides and Glycosides
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity. Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence.

HY-N6877

Purpurogallin carboxylic acid	Others	Phenols
Purpurogallin carboxylic acid, isolated from Macleaya microcarpa (Maxim.) Fedde, is an oxidation product of gallic acid in fermented tea. Purpurogallin carboxylic acid has anti-cancer activity.

HY-N8405

Isolimonexic acid	Aromatase	Terpenoids and Glycosides
Isolimonexic acid is a limonoid isolated from lemon (Citrus lemon L. Burm) seed, has anti-cancer and anti-aromatase (IC₅₀=25.60 μM) properties.

HY-N0183

Formononetin Biochanin B; Flavosil; Formononetol	FGFR Apoptosis	Flavonoids
Formononetin is a potent FGFR2 inhibitor with an IC₅₀ of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth.

HY-125916

Pseurotin A	Others	Alkaloids
Pseurotin A, a secondary metabolite of Aspergillus and other fungi, is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC₅₀=3.6 μM). Antitumor activity.

HY-N2058

Neogambogic acid	Bacterial Apoptosis	Acids and Aldehydes
Neogambogic acid, an active ingredient in garcinia, induces apoptosis and has anticancer effect. Neogambogic acid has significant inhibitory activity toward methicillin-resistant Staphylococcus aureus (MRSA).

HY-N0104

Curcumol (-)-Curcumol	Apoptosis	Terpenoids and Glycosides
Curcumol ((-)-Curcumol), a bioactive sesquiterpenoid, possesses numerous pharmacological activities like anticancer, antimicrobial, antifungal, antiviral, and antiinflammatory. Curcumol is a potent inducer of apoptosis in numerous cancer cells via targeting key signaling pathways as MAPK/ERK, PI3K/Akt and NF-κB which are generally deregulated in several cancers.

HY-N7678

Gypenoside LXXV	Others	Saccharides and Glycosides
Gypenoside LXXV, isolated from Gynostemma pentaphyllum, is one of the deglycosylated shapes of ginsenoside Rb1. Gypenoside LXXV significantly reduces cancer cell viability and displays an anti-cancer effect.

HY-139058

23-epi-26-Deoxyactein
27-Deoxyactein
Others Terpenoids and Glycosides

23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.

HY-N1506

Ganodermanontriol	Others	Terpenoids and Glycosides Steroids
Ganodermanontriol, a sterol isolated from Ganoderma lucidum, induces anti-inflammatory activity in tert-butyl hydroperoxide (t-BHP)-damaged hepatic cells through the expression of HO-1. Ganodermanontriol exhibits hepatoprotective activity.

HY-N2521

Tetramethylcurcumin FLLL31	STAT Apoptosis	Phenols
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects.

HY-N0484

Liensinine	Autophagy Mitophagy Apoptosis	Alkaloids
Liensinine is an autophagy/mitophagy inhibitor. Liensinine, a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn, has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc.

HY-N0171A

Beta-Sitosterol (purity>98%) β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%)	Apoptosis	Steroids
Beta-Sitosterol (purity>98%) is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171B

Beta-Sitosterol (purity>75%) β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%)	Apoptosis	Steroids
Beta-Sitosterol (purity>75%) includes 75% β-sitosterol and 10% campesterol. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>75%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171

Beta-Sitosterol (purity>80%) β-Sitosterol (purity>80%); 22,23-Dihydrostigmasterol (purity>80%)	Endogenous Metabolite Apoptosis	Steroids
Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

Cat. No.	Product Name	Species	Source

HY-P71043

SNCG Protein, Human
Gamma-Synuclein; breast Cancer-Specific Gene 1 Protein; Persyn; Synoretin; SR; SNCG; BCSG1; PERSYN; PRSN
Human E. coli

HY-P7677

BIN2 Protein, Human (His) rHuBIN2, His; Bridging Integrator 2; breast Cancer-Associated Protein 1; BIN2; BRAP1	Human	E. coli
BIN2 Protein, Human (His) is a recombinant human bridging integrator 2 (BIN2) with a His tag.

HY-P71072

TFF1 Protein, Human (HEK 293, His)
Trefoil factor 1; breast cancer estrogen-inducible protein; PNR-2; Polypeptide P1.A; hP1.A; Protein Ps2; TFF1; BCEI; PS2
Human HEK 293

HY-P7649

BCAS2 Protein, Human (His, T7) rHuBCAS2, His, N-T7; Pre-mRNA-Splicing Factor SPF27; breast Carcinoma-Amplified Sequence 2; Spliceosome-Associated Protein SPF 27; BCAS2	Human	E. coli
BCAS2 Protein, Human (His, T7) plays crucial roles in pre-mRNA splicing and androgen receptor transcription. BCAS2 helps repair radiation-induced DSBs efficiently in both human PCa cells and Drosophila^[1]^[2].

HY-P70301

Mucin-1 Protein, Human (HEK 293, Fc) rHuMucin-1, Fc; Mucin-1; MUC-1; breast carcinoma-associated antigen DF3; Cancer antigen 15-3; CA 15-3; Carcinoma-associated mucin; Episialin; H23AG; Krebs von den Lungen-6; KL-6; PEMT; Peanut-reactive urinary mucin; PUM; Polymorphic epithelial mucin; PEM; Tumor-associated epithelial membrane antigen; EMA; Tumor-associated mucin; CD227; MUC1	Human	HEK 293

Cat. No.	Product Name

HY-50767S

Palbociclib D8
Palbociclib D8 (PD 0332991 D8) is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research.

HY-14248S

Letrozole-d4
Letrozole-d4 (CGS 20267-d4) is the deuterium labeled Letrozole. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC₅₀ of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer.

HY-14171S

Bexarotene D4
Bexarotene D4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma.

HY-N0411S

β-Carotene-d10

β-Carotene-d10 (Provitamin A-d1) is the deuterium labeled β-Carotene. β-Carotene (Provitamin A), a carotenoid compound, is a naturally-occurring vitamin A precursor. β-Carotene is a modulator of reactive oxygen species (ROS), with antioxidant and antiinflammatory activities. β-Carotene may serve as an antioxidant or as a prooxidant, depending on its intrinsic properties as well as on the redox potential of the biological environment in which it acts. β-Carotene induces breast cancer cells apoptosis, with anticancer activities.

HY-13757AS

Tamoxifen-d5
Tamoxifen-d5 (ICI 47699-d5) is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity.

breast

Inhibitors & Agonists

Screening Libraries

Dye Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products